Evidence map›Paper›PMID 20634958›Full record

ArticlePloS one2010

Impairment of protein trafficking upon overexpression and mutation of optineurin.

BumChan Park, Hongyu Ying, Xiang Shen, Jeong-Seok Park, Ye Qiu, Rajalekshmy Shyam, Beatrice Y J T Yue

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed
7.1field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 68 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Neuroprotective Effects of Transferrin in Experimental Glaucoma Models.International journal of molecular sciences · 2022
    Article
  5. At the heart of mitochondrial quality control: many roads to the top.Cellular and molecular life sciences : CMLS · 2021
    Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Review
  13. Review
  14. Article
  15. Article
  16. Optineurin: The autophagy connection.Experimental eye research · 2016
    Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

BumChan ParkDepartment of Ophthalmology and Visual Sciences, University of Illinois at Chicago College of Medicine, Chicago, Illinois, United States of America.
Hongyu Ying
Xiang Shen
Jeong-Seok Park
Ye Qiu
Rajalekshmy Shyam
Beatrice Y J T Yue
University of Illinois Chicago · US

Funding

Translational Core for Therapeutic and Diagnostic DevelopmentP30EY001792 · NEI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI MCANANY, JAMES JASON · 1985 to 2025
$14.8M
BIOLOGY OF TRABECULAR MESHWORK IN HEALTH &DISEASER01EY005628 · NEI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI YUE, BEATRICE Y.J.T. · 1985 to 2009
$3.4M
CONNECTIVE TISSUE AND RNA STUDIES OF DISEASED CORNEASR01EY003890 · NEI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI YUE, BEATRICE Y.J.T. · 1985 to 2007
$3.0M
Cellular Processing of Optineurin, the Product of a Glaucoma GeneR01EY018828 · NEI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI YUE, BEATRICE Y.J.T. · 2009 to 2012
$1.7M
NEI NIH HHS EY003890NEI NIH HHS EY005628NEI NIH HHS EY01792NEI NIH HHS EY018828NEI NIH HHS P30 EY001792NEI NIH HHS R01 EY003890NEI NIH HHS R01 EY005628NEI NIH HHS R01 EY018828
6 · The paper itself

Abstract

backgroundGlaucoma is a major blinding disease characterized by progressive loss of retinal ganglion cells (RGCs) and axons. Optineurin is one of the candidate genes identified so far. A mutation of Glu(50) to Lys (E50K) has been reported to be associated with a more progressive and severe disease. Optineurin, known to interact with Rab8, myosin VI and transferrin receptor (TfR), was speculated to have a role in protein trafficking. Here we determined whether, and how optineurin overexpression and E50K mutation affect the internalization of transferrin (Tf), widely used as a marker for receptor-mediated endocytosis. METHODOLOGY/PRINCIPAL

findingsHuman retinal pigment epithelial (RPE) and rat RGC5 cells transfected to overexpress wild type optineurin were incubated with Texas Red-Tf to evaluate Tf uptake. Granular structures or dots referred to as foci formed in perinuclear regions after transfection. An impairment of the Tf uptake was in addition observed in transfected cells. Compared to overexpression of the wild type, E50K mutation yielded an increased foci formation and a more pronounced defect in Tf uptake. Co-transfection with TfR, but not Rab8 or myosin VI, construct rescued the optineurin inhibitory effect, suggesting that TfR was the factor involved in the trafficking phenotype. Forced expression of both wild type and E50K optineurin rendered TfR to colocalize with the foci. Surface biotinylation experiments showed that the surface level of TfR was also reduced, leading presumably to an impeded Tf uptake. A non-consequential Leu(157) to Ala (L157A) mutation that displayed much reduced foci formation and TfR binding had normal TfR distribution, normal surface TfR level and normal Tf internalization. CONCLUSIONS/SIGNIFICANCE: The present study demonstrates that overexpression of wild type optineurin results in impairment of the Tf uptake in RPE and RGC5 cells. The phenotype is related to the optineurin interaction with TfR. Our results further indicate that E50K induces more dramatic effects than the wild type optineurin, and is thus a gain-of-function mutation. The defective protein trafficking may be one of the underlying bases why glaucoma pathology develops in patients with E50K mutation.

Indexed as

MutationAnimalsCell Cycle ProteinsCell LineEndocytosisHumansImmunoblottingMembrane Transport ProteinsMicroscopy, FluorescenceProtein TransportRatsReceptors, TransferrinRNA, Small InterferingTranscription Factor TFIIIATransferrinCell Cycle ProteinsMembrane Transport ProteinsOPTN protein, humanReceptors, TransferrinRNA, Small InterferingTranscription Factor TFIIIATransferrin

Identifiers

PMID20634958
PMCPMC2902519
OpenAlexW2047193578

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.